Additionally, a recent study using four computational tools evaluated men with prostate cancer from the TCGA and found that LRP1b was one of the top 10 most frequent driver mutations, present in approximately 3.9% of tumors.30 In our heavily treated cohort, 22% (4/18) of the men with genomic profiling available had LRP1b loss or mutation present. Here, LRP1B is linked to prostate carcinoma.